Marlio Charles Mosseri
CIK: 0001806384
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Nuvectis Pharma, Inc.
Discretionary Trading P&L
Holdings
Transaction History (26 total)
- Jun 30, 2026NVCT
Nuvectis Pharma, Inc.
Purchase(P)Indirect50K shares at avg. $18.32$916K - Oct 27, 2025NVCT
Nuvectis Pharma, Inc.
Purchase(P)Indirect72.8K shares at avg. $6.28$457K - Oct 24, 2025NVCT
Nuvectis Pharma, Inc.
Purchase(P)Indirect35K shares at avg. $6.15$215K - Oct 23, 2025NVCT
Nuvectis Pharma, Inc.
Purchase(P)Indirect46.9K shares at avg. $6.06$284K - Jun 20, 2025NVCT
Nuvectis Pharma, Inc.
Purchase(P)Indirect5.6K shares at avg. $7.99$45K - Jun 18, 2025NVCT
Nuvectis Pharma, Inc.
Purchase(P)Indirect28K shares at avg. $8.05$226K - Jun 17, 2025NVCT
Nuvectis Pharma, Inc.
Purchase(P)Indirect5.4K shares at avg. $8.11$44K - May 12, 2025NVCT
Nuvectis Pharma, Inc.
Purchase(P)Indirect21.2K shares at avg. $8.11$172K - May 9, 2025NVCT
Nuvectis Pharma, Inc.
Purchase(P)Indirect9.9K shares at avg. $8.95$88K - May 9, 2025NVCT
Nuvectis Pharma, Inc.
Purchase(P)Indirect9.8K shares at avg. $8.90$87K - May 9, 2025NVCT
Nuvectis Pharma, Inc.
Purchase(P)Indirect5.4K shares at avg. $8.98$48K - May 8, 2025NVCT
Nuvectis Pharma, Inc.
Purchase(P)Indirect100 shares at avg. $8.71$871 - May 8, 2025NVCT
Nuvectis Pharma, Inc.
Purchase(P)Indirect2.4K shares at avg. $8.97$22K - May 8, 2025NVCT
Nuvectis Pharma, Inc.
Purchase(P)Indirect100 shares at avg. $8.99$899 - May 8, 2025NVCT
Nuvectis Pharma, Inc.
Purchase(P)Indirect100 shares at avg. $8.65$865 - May 8, 2025NVCT
Nuvectis Pharma, Inc.
Purchase(P)Indirect100 shares at avg. $8.65$865 - May 8, 2025NVCT
Nuvectis Pharma, Inc.
Purchase(P)Indirect2.4K shares at avg. $8.65$21K - May 8, 2025NVCT
Nuvectis Pharma, Inc.
Purchase(P)Indirect50 shares at avg. $8.65$432.5 - May 7, 2025NVCT
Nuvectis Pharma, Inc.
Purchase(P)Indirect2.7K shares at avg. $8.40$23K - May 7, 2025NVCT
Nuvectis Pharma, Inc.
Purchase(P)Indirect9.6K shares at avg. $8.64$83K - May 6, 2025NVCT
Nuvectis Pharma, Inc.
Purchase(P)Indirect2.3K shares at avg. $8.40$20K - May 6, 2025NVCT
Nuvectis Pharma, Inc.
Purchase(P)Indirect10.1K shares at avg. $8.64$87K - Feb 7, 2025NVCT
Nuvectis Pharma, Inc.
Purchase(P)Indirect240K shares at avg. $5.00$1.2M - Dec 13, 2024NVCT
Nuvectis Pharma, Inc.
Purchase(P)Direct17K shares at avg. $4.70$80K - Dec 13, 2024NVCT
Nuvectis Pharma, Inc.
Purchase(P)Direct17K shares at avg. $4.70$80K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 30, 2026 | NVCT Nuvectis Pharma, Inc. | Purchase(P) | 50,000 | $18.32 | $916,000 | Indirect |
| Oct 27, 2025 | NVCT Nuvectis Pharma, Inc. | Purchase(P) | 72,836 | $6.28 | $457,410 | Indirect |
| Oct 24, 2025 | NVCT Nuvectis Pharma, Inc. | Purchase(P) | 35,034 | $6.15 | $215,459 | Indirect |
| Oct 23, 2025 | NVCT Nuvectis Pharma, Inc. | Purchase(P) | 46,900 | $6.06 | $284,214 | Indirect |
| Jun 20, 2025 | NVCT Nuvectis Pharma, Inc. | Purchase(P) | 5,603 | $7.99 | $44,768 | Indirect |
| Jun 18, 2025 | NVCT Nuvectis Pharma, Inc. | Purchase(P) | 28,043 | $8.05 | $225,746 | Indirect |
| Jun 17, 2025 | NVCT Nuvectis Pharma, Inc. | Purchase(P) | 5,399 | $8.11 | $43,786 | Indirect |
| May 12, 2025 | NVCT Nuvectis Pharma, Inc. | Purchase(P) | 21,167 | $8.11 | $171,664 | Indirect |
| May 9, 2025 | NVCT Nuvectis Pharma, Inc. | Purchase(P) | 9,850 | $8.95 | $88,128 | Indirect |
| May 9, 2025 | NVCT Nuvectis Pharma, Inc. | Purchase(P) | 9,817 | $8.90 | $87,412 | Indirect |
| May 9, 2025 | NVCT Nuvectis Pharma, Inc. | Purchase(P) | 5,395 | $8.98 | $48,426 | Indirect |
| May 8, 2025 | NVCT Nuvectis Pharma, Inc. | Purchase(P) | 100 | $8.71 | $871 | Indirect |
| May 8, 2025 | NVCT Nuvectis Pharma, Inc. | Purchase(P) | 2,400 | $8.97 | $21,528 | Indirect |
| May 8, 2025 | NVCT Nuvectis Pharma, Inc. | Purchase(P) | 100 | $8.99 | $899 | Indirect |
| May 8, 2025 | NVCT Nuvectis Pharma, Inc. | Purchase(P) | 100 | $8.65 | $865 | Indirect |
| May 8, 2025 | NVCT Nuvectis Pharma, Inc. | Purchase(P) | 100 | $8.65 | $865 | Indirect |
| May 8, 2025 | NVCT Nuvectis Pharma, Inc. | Purchase(P) | 2,400 | $8.65 | $20,760 | Indirect |
| May 8, 2025 | NVCT Nuvectis Pharma, Inc. | Purchase(P) | 50 | $8.65 | $433 | Indirect |
| May 7, 2025 | NVCT Nuvectis Pharma, Inc. | Purchase(P) | 2,703 | $8.40 | $22,705 | Indirect |
| May 7, 2025 | NVCT Nuvectis Pharma, Inc. | Purchase(P) | 9,614 | $8.64 | $83,065 | Indirect |
| May 6, 2025 | NVCT Nuvectis Pharma, Inc. | Purchase(P) | 2,340 | $8.40 | $19,656 | Indirect |
| May 6, 2025 | NVCT Nuvectis Pharma, Inc. | Purchase(P) | 10,104 | $8.64 | $87,299 | Indirect |
| Feb 7, 2025 | NVCT Nuvectis Pharma, Inc. | Purchase(P) | 240,000 | $5.00 | $1,200,000 | Indirect |
| Dec 13, 2024 | NVCT Nuvectis Pharma, Inc. | Purchase(P) | 17,000 | $4.70 | $79,900 | Direct |
| Dec 13, 2024 | NVCT Nuvectis Pharma, Inc. | Purchase(P) | 17,000 | $4.70 | $79,900 | Direct |
1-25 of 26 transactions
About Mosseri Marlio Charles
Mosseri Marlio Charles (SEC CIK 0001806384) files insider reports with the SEC as 10% Owner of Nuvectis Pharma, Inc. (NVCT).
Signal8 holds 10 ownership filings by Mosseri Marlio Charles, all Form 4s, filed between Dec 16, 2024 and Jul 1, 2026. Those filings report 26 transactions, from Dec 12, 2024 to Jun 30, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Mosseri Marlio Charles's filings is in LONDON.
Recent filings by Mosseri Marlio Charles
- Jun 30, 2026: Open-market purchase of NVCT shares (Form 4, code P).
- Oct 27, 2025: Open-market purchase of NVCT shares (Form 4, code P).
- Oct 24, 2025: Open-market purchase of NVCT shares (Form 4, code P).
- Oct 23, 2025: Open-market purchase of NVCT shares (Form 4, code P).
- Jun 20, 2025: Open-market purchase of NVCT shares (Form 4, code P).
Other insiders filing for Nuvectis Pharma, Inc. (NVCT)
- Carson Michael J., Vice President, Finance
- BENTSUR RON, Chairman & CEO
- Hoberman Kenneth, Director
- Oliviero James F III, Director
- Sanchez Juan, Director
- Kaplan Matthew L., Director